AKRO RSI Chart
Last 7 days
-6.7%
Last 30 days
-7.0%
Last 90 days
0.2%
Trailing 12 Months
-55.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 14.0M | 0 | 0 | 24.2M |
2022 | 0 | 0 | 0 | 3.9M |
2021 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 01, 2024 | young jonathan | sold | -100,750 | 20.1499 | -5,000 | chief operating officer |
Apr 01, 2024 | young jonathan | sold | -111,903 | 24.3267 | -4,600 | chief operating officer |
Apr 01, 2024 | young jonathan | sold | -10,010 | 25.025 | -400 | chief operating officer |
Mar 13, 2024 | young jonathan | sold | -18,442 | 28.33 | -651 | chief operating officer |
Mar 13, 2024 | white william richard | sold | -20,510 | 28.33 | -724 | chief financial officer |
Mar 13, 2024 | cheng andrew | sold | -55,781 | 28.33 | -1,969 | president and ceo |
Mar 13, 2024 | yale catriona | sold | -20,482 | 28.33 | -723 | chief development officer |
Mar 13, 2024 | rolph timothy | sold | -17,536 | 28.33 | -619 | chief scientific officer |
Mar 04, 2024 | cheng andrew | acquired | 1,288,060 | 17.1742 | 75,000 | president and ceo |
Mar 04, 2024 | yale catriona | sold | -732,727 | 35.49 | -20,646 | chief development officer |
Which funds bought or sold AKRO recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 10, 2024 | CREDIT SUISSE AG/ | added | 15.26 | 232,812 | 1,175,780 | -% |
May 10, 2024 | Orion Capital Management LLC | sold off | -100 | -11,675 | - | -% |
May 10, 2024 | Cullen/Frost Bankers, Inc. | sold off | -100 | -3,503 | - | -% |
May 10, 2024 | CITIGROUP INC | added | 35.54 | 2,051,910 | 6,452,260 | -% |
May 10, 2024 | JPMORGAN CHASE & CO | added | 112 | 4,649,880 | 8,219,580 | -% |
May 10, 2024 | WELLS FARGO & COMPANY/MN | added | 40.12 | 173,006 | 508,383 | -% |
May 10, 2024 | OSAIC HOLDINGS, INC. | reduced | -12.39 | -4,131 | 75,224 | -% |
May 10, 2024 | PNC Financial Services Group, Inc. | added | 2,014 | 31,161 | 32,585 | -% |
May 10, 2024 | Covestor Ltd | reduced | -55.56 | - | - | -% |
May 10, 2024 | Y-Intercept (Hong Kong) Ltd | new | - | 338,080 | 338,080 | 0.03% |
Unveiling Akero Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Akero Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 48.2B | 6.8B | -8.07 | 7.03 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 19.0B | 2.0B | -57.12 | 9.47 | ||||
BMRN | 15.3B | 2.5B | 74.39 | 6.18 | ||||
INCY | 12.9B | 3.8B | 17.35 | 3.43 | ||||
MID-CAP | ||||||||
BBIO | 5.3B | 107.9M | -9.76 | 48.09 | ||||
APLS | 5.2B | 524.1M | -12.51 | 9.96 | ||||
AXSM | 3.6B | 251.0M | -12.12 | 14.31 | ||||
ARWR | 2.7B | 240.7M | -5.82 | 12.77 | ||||
ACAD | 2.5B | 813.8M | -1.5K | 3.08 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.44 | 4.66 | ||||
NVAX | 1.8B | 996.6M | -4.62 | 1.85 | ||||
CRBP | 458.7M | 881.7K | -13.59 | 481.06 | ||||
INO | 294.6M | 4.9M | -2.36 | 60.54 | ||||
IBIO | 15.6M | 2.1M | -0.67 | 7.61 |
Akero Therapeutics Inc News
Income Statement (Quarterly) | ||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q1 | 2022Q4 | 2021Q4 |
Revenue | 38.5% | 7,601 | 5,490 | 3,379 | - | - |
Operating Expenses | -3.1% | 59,954 | 61,873 | 28,753 | 25,420 | 32,439 |
S&GA Expenses | -100.0% | - | 8,481 | 6,966 | 7,100 | 4,728 |
R&D Expenses | -5.1% | 50,650 | 53,392 | 21,787 | 18,320 | 27,711 |
Interest Expenses | 10.5% | 991 | 897 | 457 | - | - |
Net Income | 3.3% | -53,344 | -55,186 | -25,831 | -23,059 | -32,424 |
Net Income Margin | -18.1% | -7.40* | -6.27* | -7.97* | -29.01* | - |
Free Cashflow | 27.7% | -35,140 | -48,627 | -24,632 | -25,508 | -26,695 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2018Q4 |
Assets | 57.2% | 912 | 580 | 635 | 664 | 349 | 357 | 379 | 186 | 170 | 196 | 224 | 238 | 258 | 273 | 300 | 114 | 127 | 138 | 150 | 163 | 77.00 |
Current Assets | 62.7% | 911 | 560 | 576 | 643 | 347 | 355 | 378 | 184 | 168 | 194 | 222 | 236 | 256 | 271 | 298 | 113 | 126 | 138 | 150 | 163 | 77.00 |
Cash Equivalents | 166.4% | 624 | 234 | 270 | 444 | 258 | 250 | 374 | 178 | 151 | 151 | 165 | 158 | 188 | 187 | 193 | 63.00 | 47.00 | 65.00 | 148 | 163 | 76.00 |
Net PPE | -5.6% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - |
Liabilities | 46.8% | 66.00 | 45.00 | 52.00 | 47.00 | 42.00 | 30.00 | 36.00 | 37.00 | 23.00 | 26.00 | 25.00 | 18.00 | 12.00 | 15.00 | 14.00 | 10.00 | 8.00 | 9.00 | 7.00 | 5.00 | 2.00 |
Current Liabilities | 58.2% | 30.00 | 19.00 | 28.00 | 22.00 | 17.00 | 19.00 | 25.00 | 27.00 | 22.00 | 25.00 | 24.00 | 16.00 | 10.00 | 13.00 | 12.00 | 10.00 | 8.00 | 9.00 | 7.00 | 5.00 | 2.00 |
Shareholder's Equity | 58.1% | 846 | 535 | 583 | 616 | 306 | 327 | 344 | 148 | 147 | 169 | 199 | 220 | 246 | 259 | 286 | 104 | 118 | 129 | 143 | 158 | - |
Retained Earnings | -9.3% | -627 | -574 | -518 | -479 | -448 | -422 | -399 | -363 | -336 | -310 | -277 | -253 | -224 | -209 | -179 | -158 | -142 | -130 | -114 | -99.15 | -86.56 |
Additional Paid-In Capital | 32.9% | 1,474 | 1,109 | 1,103 | 1,096 | 754 | 749 | 743 | 512 | 483 | 479 | 477 | 474 | 471 | 468 | 466 | 262 | 260 | 259 | 258 | 258 | 37.00 |
Shares Outstanding | 24.0% | 69.00 | 56.00 | 56.00 | 56.00 | 47.00 | 47.00 | 39.00 | 35.00 | 35.00 | 35.00 | 35.00 | 35.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 2,518 | - | - | - | 340,435 | - | - | - | 768 | - | - | - | 478 | - | - | - | 196 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 27.7% | -35,140 | -48,627 | -49,719 | -22,389 | -24,632 | -25,508 | -24,624 | -19,509 | -22,876 | -26,695 | -14,606 | -20,034 | -18,346 | -23,395 | -13,508 | -22,584 | -11,317 | -11,649 | -13,212 | -5,322 | -5,444 |
Share Based Compensation | 21.0% | 7,398 | 6,116 | 5,739 | 4,798 | 4,844 | 4,040 | 11,731 | 4,161 | 3,311 | 2,642 | 2,612 | 2,436 | 2,364 | 1,916 | 1,546 | 1,323 | 1,237 | 670 | 483 | 402 | 215 |
Cashflow From Investing | 352.4% | 57,849 | 12,786 | -125,697 | -128,302 | 17,590 | -101,445 | 3,000 | 11,870 | 22,750 | 12,000 | 21,934 | -10,654 | 19,000 | 17,899 | -59,844 | 38,465 | -6,281 | - | - | - | - |
Cashflow From Financing | 72995.2% | 366,938 | 502 | 806 | 336,855 | 15,153 | 2,723 | 217,900 | 34,877 | 132 | 243 | 69.00 | 266 | 24.00 | 59.00 | 202,784 | 100 | 164 | 115 | -1,607 | 98,200 | -720 |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 50,650 | $ 21,787 |
General and administrative | 9,304 | 6,966 |
Total operating expenses | 59,954 | 28,753 |
Loss from operations | (59,954) | (28,753) |
Interest expense | (991) | (457) |
Interest and other income, net | 7,601 | 3,379 |
Net loss | (53,344) | (25,831) |
Net unrealized loss on marketable securities | (349) | (16) |
Comprehensive loss | $ (53,693) | $ (25,847) |
Net loss per share, basic | $ (0.9) | $ (0.55) |
Net loss per share, diluted | $ (0.9) | $ (0.55) |
Weighted-average number of shares used in computing net loss per common share, basic | 59,307,759 | 46,944,059 |
Weighted-average number of shares used in computing net loss per common share, diluted | 59,307,759 | 46,944,059 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 623,854 | $ 234,207 |
Short-term marketable securities | 279,811 | 315,803 |
Prepaid expenses and other current assets | 7,615 | 9,952 |
Total current assets | 911,280 | 559,962 |
Long-term marketable securities | 19,283 | |
Property and equipment, net | 17 | 18 |
Right of use asset | 946 | 1,008 |
Total assets | 912,243 | 580,271 |
Current liabilities: | ||
Accounts payable | 13,783 | 7,038 |
Accrued expenses and other current liabilities | 16,476 | 12,090 |
Total current liabilities | 30,259 | 19,128 |
Loan payable, noncurrent | 34,803 | 24,964 |
Warrant liability | 178 | 54 |
Operating lease liability, noncurrent | 750 | 819 |
Total liabilities | 65,990 | 44,965 |
Commitments and contingencies (Note 12) | ||
Stockholders' equity: | ||
Common stock, $0.0001 par value, 150,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 69,148,429 and 55,754,445 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 7 | 6 |
Additional paid-in capital | 1,473,765 | 1,109,126 |
Accumulated other comprehensive (loss) income | (79) | 270 |
Accumulated deficit | (627,440) | (574,096) |
Total stockholders' equity | 846,253 | 535,306 |
Total liabilities and stockholders' equity | $ 912,243 | $ 580,271 |